DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma

Phase 1

Completed

Conditions: Malignant Glioma
Glioblastoma Multiforme

Interventions: Biological: Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L

First Posted Date: 2013-03-15

Last Posted Date: 2021-08-31

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 19

Registration Number: NCT01811992

Locations: 🇺🇸
University of Michigan Health System Department of Neurosurgery, Ann Arbor, Michigan, United States

Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy

Not Applicable

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Procedure: Resistance Exercise Training (RET)

First Posted Date: 2013-02-20

Last Posted Date: 2015-05-20

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 24

Registration Number: NCT01794481

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Veterans Affairs (VA) Ann Arbor Healthcare System, Ann Arbor, Michigan, United States

Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant

Phase 2

Completed

Conditions: Graft vs Host Disease
Hematologic Neoplasms
Non-Neoplastic Hematologic and Lymphocytic Disorder

Interventions: Drug: Vorinostat
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2013-02-13

Last Posted Date: 2018-08-13

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 26

Registration Number: NCT01790568

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

Phase 2

Active, not recruiting

Conditions: Relapsed Chronic Lymphocytic Leukemia

Interventions: Drug: Metformin

First Posted Date: 2012-12-17

Last Posted Date: 2025-02-26

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 37

Registration Number: NCT01750567

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

Phase 2

Withdrawn

Conditions: Urothelial Cancer
Bladder Cancer

Interventions: Drug: Lapatinib and Paclitaxel

First Posted Date: 2012-10-04

Last Posted Date: 2013-01-17

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT01700010

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease

Phase 2

Completed

Conditions: Graft vs Host Disease

Interventions: Drug: Alpha-1-Antitrypsin (AAT)

First Posted Date: 2012-10-04

Last Posted Date: 2018-11-27

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT01700036

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Effect of Radiation on Tissue for Delayed Breast Reconstruction

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: Skin and blood vessel procedures

First Posted Date: 2012-08-16

Last Posted Date: 2017-05-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 10

Registration Number: NCT01666899

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: CABOZANTINIB
Drug: gemcitabine

First Posted Date: 2012-08-13

Last Posted Date: 2018-09-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 12

Registration Number: NCT01663272

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer

Not Applicable

Completed

Conditions: Head and Neck Cancer

Interventions: Procedure: Saliva Sample

First Posted Date: 2012-08-13

Last Posted Date: 2014-08-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 50

Registration Number: NCT01663246

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

Phase 2

Terminated

Conditions: Bladder Cancer
Urothelial Cancer

Interventions: Drug: Neoadjuvant Cisplatin and Gemcitabine

First Posted Date: 2012-08-13

Last Posted Date: 2015-12-03

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 1

Registration Number: NCT01663285

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸
University of Rochester, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy